CG Oncology, Inc. CGON
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1,030.31% | 666.01% | 254.70% | 217.84% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,030.31% | 666.01% | 254.70% | 217.84% | -- |
| Cost of Revenue | 59.44% | 52.14% | 47.73% | 60.60% | -- |
| Gross Profit | -54.33% | -47.70% | -44.82% | -59.09% | -- |
| SG&A Expenses | 73.10% | 86.21% | 118.16% | 168.80% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 63.99% | 62.91% | 68.23% | 88.60% | -- |
| Operating Income | -60.61% | -59.94% | -66.37% | -87.68% | -- |
| Income Before Tax | -75.18% | -76.91% | -82.87% | -108.09% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -75.18% | -76.91% | -82.87% | -108.09% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -75.18% | -76.91% | -82.87% | -108.09% | -- |
| EBIT | -60.61% | -59.94% | -66.37% | -87.68% | -- |
| EBITDA | -58.93% | -58.32% | -65.16% | -87.13% | -- |
| EPS Basic | -53.14% | -56.16% | -47.93% | 61.77% | -- |
| Normalized Basic EPS | -53.15% | -56.16% | -47.93% | 51.20% | -- |
| EPS Diluted | -53.14% | -56.16% | -47.93% | 61.77% | -- |
| Normalized Diluted EPS | -53.15% | -56.16% | -47.93% | 51.20% | -- |
| Average Basic Shares Outstanding | 14.17% | 13.80% | 23.73% | 60.30% | -- |
| Average Diluted Shares Outstanding | 14.17% | 13.80% | 23.73% | 60.30% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |